| Patient | Frédéric Chopin |
|---|---|
| Date of birth | 1998-03-01 |
| Identifiers | MRN HR-NI020-SYN; SSN (made up) 000-20-8845 |
| Document date | 2026-11-01 |
| Author | Matthias Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three months of cough, two weeks of blood-streaked sputum, night sweats, and weight loss: chest X-ray and CT, sputum samples, blood tests, home airborne isolation, and a report of suspected tuberculosis to the health department. Concerns: He has coughed for about three months, now with streaks of blood, sweats at night, and has lost weight; he wants to know what is wrong; He teaches piano at home and performs; he wants to know when he can teach again and whether his students are at risk; He is afraid his students and neighbors will shun him if they learn he may have tuberculosis. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food | 1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses) | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Moxifloxacin 400 mg tablet, one tablet daily | 400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours after | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeks | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg) | Oral route | 2026-03-20 to 2026-05-14 | completed | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Chest X-ray, two views: right upper lobe consolidation with a 2.5 cm thick-walled cavity and patchy opacities in the left upper zone; no effusion | 2026-03-17 to 2026-03-17 | completed | S |
| CT of the chest without contrast: a 2.5 cm thick-walled cavity in the apical segment of the right upper lobe with surrounding consolidation and tree-in-bud nodules in both upper lobes; no bronchiectasis, no emphysema, no enlarged lymph nodes, no effusion | 2026-03-17 to 2026-03-17 | completed | S |
| Chest X-ray, two views, at the end of treatment: cavity closed, with a small area of right upper lobe scarring; kept as the baseline for any future comparison | 2026-07-21 to 2026-07-21 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2023-10-04 | Tetanus, diphtheria, and pertussis (Tdap) booster | completed | S |
| 2026-09-15 | Influenza vaccine, 2026-2027 season | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1820s | Recurrent episodes of cough, fever, headaches, and swollen lymph nodes in his teens | D (CLM-0004) |
| winter of 1836 to 1837 | Serious illness; cause not recorded in the cited source | D (CLM-0007) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| sister | Tuberculosis; died of it in 1827 | D (CLM-0003) |
| Concern | Status | Evidence |
|---|---|---|
| He has coughed for about three months, now with streaks of blood, sweats at night, and has lost weight; he wants to know what is wrong | active | S |
| He teaches piano at home and performs; he wants to know when he can teach again and whether his students are at risk | active | S |
| He is afraid his students and neighbors will shun him if they learn he may have tuberculosis | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.1 on 2026-07-21; Leukocytes [#/volume] in Blood by Automated count 9.6 on 2026-03-17; Platelets [#/volume] in Blood by Automated count 442 on 2026-03-17; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-07-21; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 on 2026-05-15; Bilirubin.total [Mass/volume] in Serum or Plasma 0.6 on 2026-05-15; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 84 on 2026-03-17; Albumin [Mass/volume] in Serum or Plasma 4 on 2026-07-21; Creatinine [Mass/volume] in Serum or Plasma 0.78 on 2026-03-17; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 125 on 2026-03-17; Glucose [Mass/volume] in Serum or Plasma 86 on 2026-03-17; Potassium [Moles/volume] in Serum or Plasma 4 on 2026-03-17; Calcium [Mass/volume] in Serum or Plasma 9 on 2026-03-17; Magnesium [Mass/volume] in Serum or Plasma 2 on 2026-03-17; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-07-21; Total score [AUDIT-C] 2 on 2026-09-15; Chloride [Moles/volume] in Sweat 18 on 2026-04-07; Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma by Nephelometry 142 on 2026-04-07; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-15 [S]
Strengths and supports: Born in Poland to a French father and a Polish mother; left home at 20 and has not been back; sources of support he names: a close circle of friends from home, his students, and his music [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and culture | resolved | confirmed | R04.2 | S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit. |
| Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic. |
| Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dL | resolved | confirmed | E44.0 | S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion. |
| Acute viral upper respiratory infection during the continuation phase of tuberculosis treatment; resolved | resolved | confirmed | J06.9 | S — Synthetic intercurrent illness chosen to teach how to tell a cold from tuberculosis treatment failure, and moxifloxacin interactions with cold remedies; it does not echo a documented illness. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-17 | Hemoglobin [Mass/volume] in Blood | 12.1 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-03-17 | Leukocytes [#/volume] in Blood by Automated count | 9.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-03-17 | Platelets [#/volume] in Blood by Automated count | 442 | 10*3/uL | 150-400 10*3/uL | High | S |
| 2026-03-17 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-56 U/L | Normal | S |
| 2026-03-17 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 10-40 U/L | Normal | S |
| 2026-03-17 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-03-17 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 84 | U/L | 40-129 U/L | Normal | S |
| 2026-03-17 | Albumin [Mass/volume] in Serum or Plasma | 3.2 | g/dL | 3.5-5 g/dL | Low | S |
| 2026-03-17 | Creatinine [Mass/volume] in Serum or Plasma | 0.78 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-17 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 125 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-17 | Glucose [Mass/volume] in Serum or Plasma | 86 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-17 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-17 | Calcium [Mass/volume] in Serum or Plasma | 9 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-17 | Magnesium [Mass/volume] in Serum or Plasma | 2 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-03-17 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 2026-03-17 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-04-07 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 34 | U/L | 7-56 U/L | Normal | S |
| 2026-04-07 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 10-40 U/L | Normal | S |
| 2026-04-07 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-04-07 | Chloride [Moles/volume] in Sweat | 18 | mmol/L | <=29 mmol/L | Normal | S |
| 2026-04-07 | Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma by Nephelometry | 142 | mg/dL | 100-190 mg/dL | Normal | S |
| 2026-05-15 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 7-56 U/L | Normal | S |
| 2026-05-15 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 10-40 U/L | Normal | S |
| 2026-05-15 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.6 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-05-15 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 13.2-16.6 g/dL | Low | S |
| 2026-05-15 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-07-21 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-07-21 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-07-21 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-56 U/L | Normal | S |
| 2026-07-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-09-15 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-09-15 | Total score [AUDIT-C] | 2 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-17 | Body height | 170 | cm | S |
| 2026-03-17 | Body weight | 48.5 | kg | S |
| 2026-03-17 | Body mass index (BMI) [Ratio] | 16.8 | kg/m2 | S |
| 2026-03-17 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-03-17 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-03-17 | Heart rate | 102 | /min | S |
| 2026-03-17 | Respiratory rate | 20 | /min | S |
| 2026-03-17 | Body temperature | 37.9 | Cel | S |
| 2026-03-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 2026-03-20 | Body height | 170 | cm | S |
| 2026-03-20 | Body weight | 48.4 | kg | S |
| 2026-03-20 | Body mass index (BMI) [Ratio] | 16.7 | kg/m2 | S |
| 2026-03-20 | Systolic blood pressure | 102 | mm[Hg] | S |
| 2026-03-20 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-03-20 | Heart rate | 98 | /min | S |
| 2026-03-20 | Respiratory rate | 18 | /min | S |
| 2026-03-20 | Body temperature | 37.6 | Cel | S |
| 2026-03-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 2026-04-07 | Body height | 170 | cm | S |
| 2026-04-07 | Body weight | 49.6 | kg | S |
| 2026-04-07 | Body mass index (BMI) [Ratio] | 17.2 | kg/m2 | S |
| 2026-04-07 | Systolic blood pressure | 106 | mm[Hg] | S |
| 2026-04-07 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-04-07 | Heart rate | 86 | /min | S |
| 2026-04-07 | Respiratory rate | 16 | /min | S |
| 2026-04-07 | Body temperature | 37 | Cel | S |
| 2026-04-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-05-15 | Body height | 170 | cm | S |
| 2026-05-15 | Body weight | 52 | kg | S |
| 2026-05-15 | Body mass index (BMI) [Ratio] | 18 | kg/m2 | S |
| 2026-05-15 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-05-15 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-05-15 | Heart rate | 78 | /min | S |
| 2026-05-15 | Respiratory rate | 16 | /min | S |
| 2026-05-15 | Body temperature | 36.8 | Cel | S |
| 2026-05-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-21 | Body height | 170 | cm | S |
| 2026-07-21 | Body weight | 55 | kg | S |
| 2026-07-21 | Body mass index (BMI) [Ratio] | 19 | kg/m2 | S |
| 2026-07-21 | Systolic blood pressure | 110 | mm[Hg] | S |
| 2026-07-21 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-07-21 | Heart rate | 72 | /min | S |
| 2026-07-21 | Respiratory rate | 14 | /min | S |
| 2026-07-21 | Body temperature | 36.6 | Cel | S |
| 2026-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-09 | Body height | 170 | cm | S |
| 2026-06-09 | Body weight | 53.6 | kg | S |
| 2026-06-09 | Body mass index (BMI) [Ratio] | 18.5 | kg/m2 | S |
| 2026-06-09 | Systolic blood pressure | 108 | mm[Hg] | S |
| 2026-06-09 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 2026-06-09 | Heart rate | 88 | /min | S |
| 2026-06-09 | Respiratory rate | 16 | /min | S |
| 2026-06-09 | Body temperature | 37.6 | Cel | S |
| 2026-06-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 2026-09-15 | Body height | 170 | cm | S |
| 2026-09-15 | Body weight | 56.2 | kg | S |
| 2026-09-15 | Body mass index (BMI) [Ratio] | 19.4 | kg/m2 | S |
| 2026-09-15 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-09-15 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-09-15 | Heart rate | 70 | /min | S |
| 2026-09-15 | Respiratory rate | 14 | /min | S |
| 2026-09-15 | Body temperature | 36.6 | Cel | S |
| 2026-09-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-17 | Three months of cough, two weeks of blood-streaked sputum, night sweats, and weight loss: chest X-ray and CT, sputum samples, blood tests, home airborne isolation, and a report of suspected tuberculosis to the health department | finished | S |
| 2026-03-20 | Results visit: pulmonary tuberculosis confirmed; infectious diseases consultation and the start of the four-month rifapentine-moxifloxacin regimen by video-observed therapy | finished | S |
| 2026-04-07 | Two-and-a-half-week review: release from isolation, return to teaching, liver tests, and tests for cystic fibrosis and alpha-1 antitrypsin deficiency | finished | S |
| 2026-05-15 | End of the eight-week intensive phase: susceptibility results, the two-month sputum culture, and the start of the continuation phase | finished | S |
| 2026-07-21 | End-of-treatment review after 119 doses | finished | S |
| 2026-06-09 | Same-day sick visit for a cold with cough during tuberculosis treatment | finished | S |
| 2026-09-15 | Adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Infectious diseases consultation to confirm the diagnosis, choose between the six-month and four-month regimens, plan monitoring and his return to teaching, and address cystic fibrosis and alpha-1 antitrypsin deficiency as explanations for his lifelong chest illness | completed | GL-ATS-TB-2016, GL-CDC-4MO-2022 | S |
| Diagnosis: three sputum samples at least eight hours apart, one early in the morning, for acid-fast smear, nucleic acid amplification with rifampin resistance, culture, molecular testing for isoniazid and fluoroquinolone resistance, and phenotypic susceptibility; an interferon-gamma release assay; HIV, hepatitis B, and hepatitis C tests; and baseline blood count, liver and kidney tests, potassium, calcium, and magnesium | completed | GL-ATS-TB-2016, GL-CDC-4MO-2022 | S |
| Infection control and public health: home airborne isolation with no students or visitors and a surgical mask around others; same-day report of suspected tuberculosis to the health department; a contact investigation of his students, friends, and other close contacts led by the health department | completed | GL-CDC-CONTACT-2005, GL-ATS-TB-2016 | S |
| Nutrition: two dietitian visits in the first month, three meals and three energy-dense snacks a day, two oral nutrition supplement drinks a day, and weight at every visit | completed | GL-ASPEN-MALN-2012, GL-ATS-TB-2016 | S |
| Support: plain information about how tuberculosis spreads, how quickly treatment makes him non-infectious, and that it is curable; help with what to tell his students; PHQ-9 at diagnosis, at two months, and at the end of treatment | completed | GL-USPSTF-DEP-2023, GL-ATS-TB-2016 | S |
| Treatment: the four-month regimen of rifapentine 1200 mg, moxifloxacin 400 mg, isoniazid 300 mg, and pyrazinamide 1000 mg daily with food for eight weeks, then rifapentine, moxifloxacin, and isoniazid for nine weeks, with pyridoxine, by video-observed therapy seven days a week; complete when 119 doses are taken within five months | completed | GL-CDC-4MO-2022, GL-ATS-TB-2025, GL-ATS-TB-2016 | S |
| Monitoring: symptoms, weight, adverse effects (liver, tendons, nerves) and observed doses at every visit; liver tests at two to three weeks and for symptoms; sputum smears in the third week for release, then monthly culture until two are negative, including the two-month culture; phenotypic susceptibility including moxifloxacin; PHQ-9 at two months and at the end | completed | GL-CDC-4MO-2022, GL-ATS-HEPATOTOX-2006 | S |
| Sweat chloride test and serum alpha-1 antitrypsin level once he is out of isolation, to address cystic fibrosis and alpha-1 antitrypsin deficiency as the proposed alternatives | completed | GL-CFF-DX-2017, GL-ATS-A1AT-2003 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Complete all 119 doses within five months by video-observed therapy | 2026-07-21 | completed | All 119 doses completed in 17 weeks: 56 in the intensive phase and 63 in the continuation phase, with none missed | S |
| Sputum culture negative at two months | 2026-07-21 | completed | The two-month culture showed no growth, as did the cultures from the third week | S |
| Return to teaching once the health department confirms he is no longer infectious | 2026-04-07 | completed | Released from isolation after three negative smears and more than two weeks of treatment; teaching again from the third week | S |
| Weight back to at least 55 kg by the end of treatment | 2026-07-21 | completed | 55.0 kg at the end of treatment, from 48.5 kg at diagnosis | S |
| PHQ-9 below 5 by the end of treatment | 2026-07-21 | completed | PHQ-9 3 at the end of treatment, from 7 at diagnosis | S |